U.S. Chemicals Stock News

Polibeli Group's FY 2025 Earnings Snapshot Polibeli Group (NasdaqGM:PLBL) has reported its latest figures with trailing twelve month revenue of about US$26.4 million and a loss of US$5.97 million, translating to a basic EPS of US$0.016, alongside reported revenue growth of 32.6% over the past year. The company has seen revenue move from US$22.8 million in the twelve months to the second half of 2023 to US$26.4 million in the latest trailing period, while basic EPS moved from US$0.013 to...

Bank First Corporation has recently reported first-quarter 2026 results, completed a prior buyback of 209,412 shares for US$23.02 million, announced a new share repurchase program of up to US$60 million through April 20, 2028, and increased its quarterly dividend to US$0.55 per share. Together, the expanded buyback capacity and higher dividend highlight a stronger capital return focus that may influence how investors view Bank First’s long‑term capital allocation priorities. With these...

Rithm Property Trust (RPT) opened Q1 2026 with total revenue of US$2.9 million and basic EPS of US$0.43 loss per share, giving investors a fresh look at how the business is tracking after a volatile 2025. Over the past year, revenue has moved from US$18.3 million on a trailing basis in Q4 2025 to US$22.0 million by Q1 2026, while trailing twelve month EPS has shifted from a US$0.36 loss to a US$0.30 loss. With the share price around US$14.43, the latest release puts the spotlight squarely on...

Investors may be wondering whether Monolithic Power Systems at around US$1,632 per share is still offering value, or if expectations are already fully priced in. The stock has posted returns of 11.1% over the last 7 days, 54.2% over the last 30 days, 74.3% year to date and 181.7% over the past year, with longer term returns of 261.4% over 3 years and 368.4% over 5 years. These strong price moves have kept Monolithic Power Systems firmly on investors' watchlists, as the market reacts to...

Wealthfront (WLTH) closed FY 2026 with Q4 revenue of US$96.1 million and a basic EPS loss of US$1.30, alongside trailing 12 month revenue of US$365.0 million and a trailing basic EPS loss of US$0.74. Over the past six quarters, the company has seen quarterly revenue move from US$80.3 million in Q3 2025 to US$96.1 million in Q4 2026. Basic EPS has shifted from US$0.77 in Q3 2025 to US$0.72, US$0.86 and US$0.75 in the first three quarters of 2026 before turning to a loss of US$1.30 in Q4 2026...

Wondering if Opera's recent share price puts it in the bargain bin or the overhyped aisle? This article breaks down what the numbers say about value. At a last close of US$17.23, Opera's share price comes with recent returns of 0.6% over 7 days, 25.6% over 30 days, 21.1% year to date, 16.3% over 1 year, 67.0% over 3 years, and 105.9% over 5 years. These moves sit against a backdrop of ongoing interest in Opera as a software name, with headlines frequently focusing on its role as a browser...

Wondering if Amkor Technology at US$78.10 is priced for perfection or still offers value? This article walks you through what the current market price may be telling you. The stock has recently posted returns of 15.9% over 7 days, 73.0% over 30 days, 82.0% year to date, and 350.3% over 1 year, which can change how investors think about both upside potential and risk. These moves sit against the backdrop of ongoing attention on semiconductor supply chains and packaging capacity, as investors...

Wondering whether Palvella Therapeutics at around US$123.59 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price could mean for you. The stock has seen a 23.2% return year to date and a 386.8% return over the last year, alongside shorter term moves of a 2.7% return over 30 days and a 4.9% decline over the past week. Recent attention on Palvella Therapeutics has centered on how the market is reassessing smaller biotech names...

In April 2026, ZenaTech expanded its global drone and SaaS footprint by registering Phoenix Aero in Lviv, Ukraine, and opening new offices in Seoul and London to support manufacturing, counter-UAS testing, and regional commercial, government, and defense operations. This rapid build-out of on-the-ground teams across EMEA and APAC highlights ZenaTech’s intent to become a key provider of AI-driven autonomous drone solutions and recurring software services in multiple high-demand markets. We’ll...

If you are wondering whether Ciena's current share price reflects its true worth, the recent trading history gives you plenty to think about. The stock last closed at US$520.80, with returns of 2.6% over 7 days, 19.0% over 30 days and 111.7% year to date, plus very large returns over 1 year and the past 3 and 5 years. Recent coverage has focused on Ciena as a key player in communications technology, with attention on how its products fit into growing data and network demand. This context has...

Varonis Systems launched Atlas, an all in one AI security solution integrated with its Data Security Platform. Atlas is designed to help enterprises with AI inventory discovery, security testing, data leak prevention, and compliance. The launch adds a new AI focused layer to Varonis Systems' existing data security offering. For investors watching NasdaqGS:VRNS, Atlas lands at a time when AI security is a central concern for many enterprise IT teams. The company’s shares most recently closed...

If you are wondering whether Wintrust Financial at US$147.91 still offers value or is starting to look stretched, the recent share price and fundamentals give you some clear clues to work with. The stock has held up over the last week with a 0.2% decline. The 30 day return sits at 8.0% and the 1 year return at 35.6%, with longer term returns of 128.2% over 3 years and 108.7% over 5 years. Recent coverage has focused on Wintrust Financial as part of broader discussions around US regional...

FDA extends Priority Review for Savara’s molgramostim BLA in autoimmune PAP by three months following a major amendment. Regulator cites no new safety, efficacy, or manufacturing concerns in connection with the extension. Extension reflects ongoing review activity for Savara’s lead product candidate, ticker NasdaqGS:SVRA. Savara, listed on NasdaqGS:SVRA, focuses on therapies for rare respiratory diseases, with molgramostim as its most advanced program targeting autoimmune pulmonary alveolar...

If you are wondering whether ANI Pharmaceuticals at around US$78.64 is priced attractively or already reflects a lot of optimism, the starting point is to understand what the current share price implies about future expectations. The stock shows mixed recent returns, with a 2.8% decline over 7 days, a 6.2% gain over 30 days, a 0.3% return year to date, 12.6% over 1 year, 108.5% over 3 years and 136.3% over 5 years. Recent coverage around ANI Pharmaceuticals has focused on its position within...

If you are wondering whether TransMedics Group at around US$110.93 is still priced attractively or already baking in a lot of optimism, this article walks through the key valuation clues. The stock has had a mixed recent run, with a 4.3% pullback over the last 7 days, an 8.5% gain over 30 days, a 9.6% decline year to date, an 18.6% return over the past year, and a very large 3 year gain of around 40.2%. Recent headlines around TransMedics Group have continued to focus on its position in the...

Wondering if Axsome Therapeutics at around US$185.96 is offering fair value or stretching expectations? This breakdown will help you frame what the current price might be implying. The stock has seen a 14.9% return over the last 30 days and a 75.0% return over the last year. The year to date return sits at 4.1%, while the 7 day return is a 1.6% decline. Recent headlines around Axsome have focused on the company as a higher profile name within pharmaceuticals and biotech. This helps explain...

Instacart, listed as NasdaqGS:CART under Maplebear, has announced the acquisition of Instaleap. Instaleap operates a fulfillment and enablement platform across roughly 30 countries outside North America. The deal is intended to expand Instacart's enterprise services across Europe, Latin America, and the Middle East. Instacart's parent company Maplebear, trading at $42.17, is adding Instaleap to widen its international reach beyond its core North American base. The move comes after a 15.9%...

Verisk Analytics (NasdaqGS:VRSK) has agreed to acquire AccuLynx, a SaaS provider in the restoration and repair industry, in a pending US$2.35b deal. The company expects the transaction to support its property estimating solutions and to be accretive by the end of 2026. Recent collaborations include integrations with Roofr Inc. for insurance claim processing and Pilotbird for social media investigative reports. These moves expand Verisk's ecosystem for insurance and claims professionals...

Activist investor Land & Buildings has criticized Welltower's new executive compensation plan, describing it as unusually aggressive. The investor argues the structure could work against shareholder interests and weaken alignment between management and owners. The dispute focuses on governance and incentives at NYSE:WELL, rather than short term operating performance. For investors watching NYSE:WELL, this governance debate arrives with the shares at $208.75 and with very large longer term...

If you are wondering whether Boston Scientific at around US$62 a share is starting to look appealing on value, or if the price still has more to adjust, this article is for you. The stock has seen a 3.4% decline over the last week, an 11.0% decline over the last month, and year to date is down 34.5% with a 39.1% decline over the last year, even though the 3 year and 5 year returns sit at 19.1% and 42.4% respectively. Recent moves are playing out against a backdrop of ongoing interest in...

Maze Therapeutics (NasdaqGM:MAZE) completed a sizable underwritten public offering of common stock and pre funded warrants. The deal drew significant participation from both new and existing institutional investors. Proceeds are earmarked to advance Maze Therapeutics' research and development programs focused on serious diseases. Maze Therapeutics, trading at a recent share price of $25.81, has experienced sharp share price swings, with a 7 day return of an 8.1% decline and a 30 day return...

Tompkins Financial (TMP) opened 2026 with Q1 results that build on a strong finish to 2025, with trailing 12 month revenue of US$435.1 million and basic EPS of US$11.30 supported by Q4 2025 net income of US$96.2 million on revenue of US$193.8 million. Over the past year, revenue has moved from US$292.6 million to US$435.1 million on a trailing basis while basic EPS climbed from US$4.98 to US$11.30, alongside net profit margin at 37% versus 24.2% the prior year. This sets up a quarter where...

Wondering whether Array Technologies at US$8.11 is offering value or just noise? This article walks through what the current price might be saying about the stock. Over the short term, the share price move of 3.6% over 7 days and 4.9% over 30 days sits alongside a 16.2% decline year to date and a 61.6% return over the last year. Taken together, this gives you a very mixed picture. These moves come as Array Technologies continues to sit in a solar and renewables theme that regularly attracts...

If you are wondering whether IAC is attractively priced or if the recent buzz is already reflected in the share price, this article walks through the key signals that matter for valuation focused investors. IAC shares last closed at US$44.48, with returns of 0.3% over 7 days, 11.5% over 30 days, 13.9% year to date and 25.1% over 1 year, compared with a much weaker 3 year return of 4.3% and a 5 year return showing a 68.0% decline. Recent headlines around IAC have kept attention on how the...